B+
Bull case
0%
Probability
Target price
$8.50
+32.0% vs current
NUVB
Nuvation BioCNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-08-04
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
0%
Probability
Target price
$6.50
+0.9% vs current
B-
Bear case
0%
Probability
Target price
$4.00
-37.9% vs current
AI sentiment snapshot
Latest data as of 2026-06-19
Recent news sentiment (30D)
+0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+58.3
Score
AI commentary
Primary-source evidence is good, but the thesis is still a monitoring view rather than a high-conviction rerating call: tone is helped by the Q1 2026 business update and strong cash balance, while near-term sentiment should stay tied to proof that first-line IBTROZI adoption converts into steadier revenue growth. Social and market-structure data were not available in the packet, so confidence stays moderate rather than strong.
RankAlpha Sentiment Codex - 2026-06-19
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-01catalystIBTROZI launch mix is shifting toward first-line patientsHigh impact
Q1 2026 IBTROZI net product revenue was $18.5 million, with more than half of roughly 200 new starts TKI-naive; management framed this as early evidence of a more durable first-line revenue base, but near-term revenue can still be uneven while later-line discontinuations wash through [#SEC-8K-2026-05-04].
2026-12-31eventSafusidenib Phase 3 SIGMA execution and Japan expansionHigh impact
Nuvation said it secured exclusive global development and commercialization rights to safusidenib and plans to advance the pivotal Phase 3 SIGMA study, including Japan, which could tighten focus on the glioma program if enrollment and development milestones progress cleanly [#SEC-8K-2026-05-04].
2026-12-31catalystAdditional pipeline and platform updates later in 2026High impact
The company said it remains on track to provide updates on its drug-drug conjugate platform later in 2026, offering a second potential source of upside beyond the commercial IBTROZI launch, though visibility is still limited [#SEC-8K-2026-05-04].
Recommendation
N/A
No formal recommendation provided.
As of 2026-06-19 • Updated nightlySource: Internal modelMethodology